Florence Healthcare adds Tarek Sherif to its Board of Directors

– USA, GA –  Florence Healthcare, the industry leader in remote connectivity in clinical research, today announced the appointment of Life sciences technology veteran Tarek Sherif to its board of directors.

“Our goal is to advance cures by helping more trial site research teams than any other company,” said CEO, Ryan Jones. “In the first chapter of our story, we made clinical trial sites more efficient, and today 10,000 of them across 44 countries use Florence. We now have a unique opportunity in our next chapter to connect that site community to the full clinical development lifecycle. With Sherif, we’ve added the world’s foremost expert on serving research at scale to meet this challenge.”

About Tarek Sherif

Over 20 years, Tarek Sherif led Medidata from a startup through an IPO, to become the market leader in cloud-based solutions in the life sciences industry. Sherif will help guide Florence’s growth in that same industry. Dassault Systemes acquired Medidata for $5.8B in 2019.

“Florence recognizes the importance of placing sites and patients at the center of research,” commented Tarek Sherif. “The company’s site-first perspective solves a last-mile problem historically overlooked by technology providers in this market. I’m looking forward to working with the exceptional team at Florence to make the world a better place by deploying the best technology where the work of research gets done — the trial site.”

About Florence Healthcare

Florence’s clinical trial software helps more than 10,000 research sites in 44 countries manage their documents, data, and workflows. The Florence platform also provides remote access so sponsors and CROs can collaborate with their sites around the world. Florence users now perform 3 million remote monitoring activities each month.

For more information: https://www.florencehc.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.